← Leaderboards
Virginia D Steen
Georgetown University
$175,236
Attributed
$175,236
Total exposure
22
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $67.1K · FY2005–09$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$175,236 · 22
By mechanism
M01$175,236 · 22
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingGrantResourcesResearch PersonnelSourceUnited States National Institutes Of HealthInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseSclerodermaExerciseEchocardiographySystemic SclerodermaDiagnosisHypertension, PulmonaryPlacebosQuestionnairesBosentanLungPressure- Physical AgentClassRestClinical ResearchProspectiveClinical Course Of Disease
Grant awards (22)
EXERCISE ECHOCARDIOGRAMS IN SCLERODERMA$12,087
M01 · FY2009 · RR · contact PI
BOSENTAN VS PLACEBO IN NYHA CLASS I/II SCLERODERMA PATIENTS WITH EXERCISE INDUCE$3,452
M01 · FY2009 · RR · contact PI
EXERCISE ECHOCARDIOGRAMS IN SCLERODERMA$19,976
M01 · FY2008 · RR · contact PI
BOSENTAN VS PLACEBO IN NYHA CLASS I/II SCLERODERMA PATIENTS WITH EXERCISE INDUCE$4,281
M01 · FY2008 · RR · contact PI
THE OUTCOME OF AFRICAN AMERICAN PATIENTS WITH SCLERODERMA IN RELATIONSHIP TO AUT$1,428
M01 · FY2008 · RR · contact PI
SCOT$713
M01 · FY2008 · RR · contact PI
BOSENTAN VS PLACEBO IN NYHA CLASS L/LL SCLERODERMA PATIENTSW/PULMON HYPERTENSION$21,933
M01 · FY2007 · RR · contact PI
EXERCISE ECHOCARDIOGRAMS IN SCLERODERMA$15,256
M01 · FY2007 · RR · contact PI
MLN1202 IN PATIENTS WITH SCLERODERMA LUNG DISEASE$14,394
M01 · FY2007 · RR · contact PI
TREATMENT OF SEVERE SYSTEMIC SCLEROSIS$8,682
M01 · FY2007 · RR · contact PI
NATURAL HISTORY- SCLERODERMA & PULMONARY HYPERTENSION$4,341
M01 · FY2007 · RR · contact PI
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SYSTEM SCLEROSIS PULMONARY AVEOLITIS$1,271
M01 · FY2007 · RR · contact PI
BOSENTAN VS PLACEBO IN NYHA CLASS I/II SCLERODERMA PATIENTS WITH EXERCISE INDUCE$953
M01 · FY2007 · RR · contact PI
NATURAL HISTORY$318
M01 · FY2007 · RR · contact PI
EXERCISE ECHOCARDIOGRAMS IN SCLERODERMA$14,455
M01 · FY2006 · RR · contact PI
ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BOSENTAN$12,906
M01 · FY2006 · RR · contact PI
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SYSTEM SCLEROSIS PULMONARY AVEOLITIS$7,744
M01 · FY2006 · RR · contact PI
A MULTICENTER, PARALLEL, RANDOMIZED, CONTROLLED, ONE-YEAR STUDY OF BOVINE COL$1,033
M01 · FY2006 · RR · contact PI
NATURAL HISTORY$516
M01 · FY2006 · RR · contact PI
BOVINE COLLAGEN TYPE I VS PLACEBO IN SYSTEMIC SCLEROSIS OF 10 YEARS DURATION$8,736
M01 · FY2005 · RR
EXERCISE ECHOCARDIOGRAMS IN SCLERODERMA$4,976
M01 · FY2005 · RR
Bovine collagen type I vs placebo in systemic sclerosis of 10 yrs duration$15,785
M01 · FY2004 · RR